New drug combo aims to tackle tough lung cancer

NCT ID NCT07154290

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 7 times

Summary

This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effects. The main goal is to see if the drugs can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ubamatamab and REGN7075 (drugs that help the immune system attack cancer cells), with sarilumab (to manage side effects)
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer who have already tried standard therapies.
What could go wrong: This is a mid-stage trial, so it's not yet proven to work. Side effects from the immune system can be serious, and the drugs may not shrink tumors in most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER CARCINOMA, NON-SMALL-CELL LUNG METASTATIC NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Baylor Scott & White Health
RECRUITING

Temple, Texas, 76508, United States
Cancer Treatment Centers of America, Phoenix
RECRUITING

Goodyear, Arizona, 85338, United States
Franciscan Health
RECRUITING

Munster, Indiana, 46321, United States
Georgetown University
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic Jacksonville
RECRUITING

Jacksonville, Florida, 32224, United States
Rush University Medical Center
RECRUITING

Chicago, Illinois, 60612, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
The City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Illinois Chicago
RECRUITING

Chicago, Illinois, 60612, United States
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
University of Tennessee Medical Center
RECRUITING

Knoxville, Tennessee, 37920, United States
University of Texas Medical Branch
RECRUITING

Galveston, Texas, 77555, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.